Abstract
Introduction
With the widespread use of the prostate-specific antigen (PSA) screening test, the number of patients diagnosed with low-risk prostate cancer (LRPCa) has increased rapidly. Patients with clinical stage ≤T2a, biopsy Gleason sum ≤6 and PSA ≤10 ng/mL are defined as low-risk prostate cancer by D'Amico and colleagues. 1 Various treatment options, ranging from active surveillance to ablative therapies (i.e., radiation therapy, cryotherapy) to radical prostatectomy (RP), are currently avaliable for pat ients with low-risk prostate cancer. The choice of treatment is often based on the prostate biopsy Gleason score (GS). So an understanding of the features of the prostate biopsy allow us to better counsel prostate cancer patients during their treatment decision process.
Because GS upgrading at prostatectomy has been associated with poorer outcomes, the factors that affect the discrepancy between biopsy and prostatectomy GS must properly assessed. King and colleagues define clinically significant upgrading of the biopsy in 2 ways: (1) biopsy GS ≤6 to prostatectomy GS ≥7 and (2) biopsy GS 3+4 to prostatectomy GS 4+3 or higher. 2 Although different biopsy methodologies were used, the upgrading rates of recent studies change from about 20% to 50%. [3] [4] [5] [6] [7] We investigate the predictive value of prostate biospy features for predicting GS upgrading in patients with biopsy GS ≤6 who underwent RP.
Methods
We performed a retrospective study of patients who underwent RP for clinically localized prostate cancer at 2 major research hospitals in Ankara, Turkey between January 2007 and March 2013. There were 442 patients who had biopsy and underwent RP. We excluded patients with missing data for biopsy GS, unknown RP GS status, pre-treatment PSA and patients with <10 cores sampled. We also excluded patients who had GS ≥7 on biopsy. In the end, we included 321 patients. All patients with either abnormal digital examination or elevated PSA at screening underwent transrectal ultrasound (TRUS)-guided prostate biopsy by urologists at the 2 centres. The prostate was biopsied near the base, mid-gland, and apex, bilaterally, with 5 or 6 biopsies per side. Essentially, 10 to 12 baseline biopsy cores were obtained in all subjects, and additional biopsies were obtaPredictors of Gleason score upgrading in patients with prostate biopsy Gleason score ≤6 original research Predictors of gleason score ined to include suspicious appearing lesions if needed. RP was done by an open retropubic or laparoscopic approach. Prostate specimens after RP were step-sectioned at 3-mm intervals and entire specimens were examined as quarter mounts. GS, extraprostatic extension, seminal vesicle invasion and surgical margins were assessed according to a predefined template. A surgical margin was considered positive when prostate glands were present at the inked margin. Extracapsular extension was defined as tumour invasion into the periprostatic tissue. Pathological specimens were examined by experienced genitourinary pathologists. With approval from each institutional review board, we analyzed the clinical and pathological data.
The following initial diagnosis-related and prostatectomyrelated variables were collected: age, pre-biopsy PSA level, PSA density, prostate biopsy GS, prostate volume, number of positive biopsy cores, highest percentage of cancer in a biopsy core, mean core length, distribution of positive foci in biopsy specimen (in one lobe or both lobes), prostatectomy Gleason score, capsular invasion,margin status, extracapsular extension and seminal vesicle invasion. Because previous studies show a high correlation between TRUS volume and pathological prostate weight, we used pathological prostate weight as prostate volume. 8, 9 Patients were divided into groups according to age, PSA levels, PSA density, prostate weights, number of positive biopsy cores, highest percentage of cancer in a biopsy core and distribution of positive foci. These variables were evaluated in patients with and without GS upgrading. Continuous variables were compared using the Mann-Whitney test and categorical variables were compared using the Pearson chi square or Fisher exact test. Multivariate Cox proportional hazards analysis was performed to identify independent predictors of GS upgrading after RP. Multivariate logistic analysis of predictors of upgrading included patient age, preoperative PSA, prostate volume <40 cc, number of cores positive for cancer, maximum percent of cancer in any core and time since surgery (days). A p value of 0.05 was considered statistically significant. All statistical analyses were performed by SPSS software (SPSS Inc, Chicago, IL). The results are expressed as the mean ± standard deviation (SD).
Results
In total, 321 men were included in our study. Of these, 190 (59.2%) patients had a GS ≤6 on prostate biopsy and 131 (40.8%) men had GS upgrading from GS ≤6 on prostate biopsy to GS 7 or higher at RP ( Table 1 ). The final GS was 3+4 in 97 (30.2%), 4+3 (8.1%) in 26, and 8-9 in 8 patients (2.5%). The overall median follow-up time was 13.4 months (range: 0.3-43).
Patients of both groups were similar in age and preoperative PSA levels ( Table 2 ). The upgraded group had significantly less than 40 cc (21.6% vs. 53.4%) TRUS prostate volumes (p < 0.001) and higher PSA density (0.20 ± 0.15 vs. 0.25 ± 0.19, respectively, p = 0.003). More patients in the upgraded group had more than 1 positive core (73.3% vs. 25.3%; p < 0.001) and a maximum percent of cancer in any core (41 ± 29 vs. 28 ± 22; p < 0.001) than in the non-upgraded group.
In the multivariate logistic regression analysis, prostate volume <40 cc (p < 0.001), maximum percent of cancer in any core (p = 0.011), and >1 core positive for cancer (p < 0.001) were independent predictors of pathological upgrading. In our study, age, PSA and time since surgery failed to predict GS upgrading (Table 3) .
We compared the pathologic outcome at RP between the GP non-upgraded group and the upgraded group (Table 4) . Pathological adverse outcomes, such as capsular invasion, extracapsular extension, seminal vesicle invasion and positive surgical margins, were associated with GS ≤6 biopsy patients who were upgraded postopereratively.
Discussion
Although many factors are taken into consideration to determine treatment, managing prostate cancer patients is often based on the biopsy GS. It has been well-documented that the prostatectomy GS differs from biopsy GS.
10-12 D'Amico and colleagues found that about 40% of men with GS ≤6 at biopsy had high-grade disease at prostatectomy. 13 Therefore, the discrepancy between biopsy and prostatectomy GS must be properly assessed and understood. We determine the predictors of GS upgrading and offer guidance to clinicians in determining the best therapeutic option for their patients.
Considering the equal proportion of high-grade disease across all prostate tissue and the equal numbers of biopsy cores taken, the detection of high-grade disease is decreased in larger prostates. Therefore, larger glands would likely be upgraded because smaller tissue would be evaluated. In early studies, researchers have described a sampling artifact or detection bias in larger prostates and these may sarici et al.
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have led to GS upgrading in larger prostates. 14, 15 An explanation for missing high-grade cancer on biopsy would be biopsy under-sampling (sextant core biopsy) of the prostate. However, recent data, which used extended biopsy schemes to evaluate the effect of prostate volume on GS upgrading, have suggested the reverse -smaller glands are more likely to be upgraded. 4, 7, 9, 16, 17 Our results also confirm the inverse relationship between volume and GS upgrading. We suggest that, when the extended core biopsy was taken, smaller prostates significantly were more likely to be upgraded. This may be related with lower androgenicity or lower levels of growth factors, such as insulin-like growth factor that can affect prostate cancer growth and differentiation. 9, [18] [19] [20] Supporting this theory, Freedland and colleagues found that patients with prostate cancer with smaller glands have more high-grade and aggressive disease. 18 Men with a larger prostate have a higher PSA level, leading to an earlier biopsy for diagnosis of prostate cancer, so low-grade cancer can be detected earlier. This theory can also explain that larger prostates are less likely to be upgraded. However, these hypotheses have not yet been fully elucidated.
The effect of PSA levels on GS upgrading has been examined; however, only a few studies have investigated the effect of PSA density on the risk of GS upgrading. In our study, we found that the frequency of upgrading was higher in the elevated PSA density group. Kundu and colleagues found that patients with higher PSA density had more aggressive clinically localized prostate cancer. 21 Also, Freedland and colleagues found that higher PSA density levels were associated with higher grade disease. 22 This finding also can be helpful in understand the association between smaller prostates and higher GS upgrading. In similar PSA serum levels, smaller prostates have higher PSA density levels and would therefore have high-grade cancer.
Tumour burden is also another risk factor for GS upgrading. Although their study is limited by a small patient population, Dong and colleagues found that >1 biopsy core or greater than 10% of any positive cores for prostate cancer may be predict upgrading. 7 Similarly Serkin and colleagues found that patients with an increased burden of cancer on biopsy are likely to be upgraded. 16 We found that the num- Predictors of gleason score ber of positive cores and the highest percentage of cancer involvement of any core on biopsy are also important predictor factors of GS upgrading risk. Specifically, patients with >1 positive core are 5.982 times more likely to have GS upgrading. When we analyzed the patients who were upgraded, we found that the occurrence of capsular invasion, extraprostatic extension, positive surgical margin and seminal vesicle invasion were all significantly increased. We know that patients with these parameters at prostatectomy have poorer outcomes, such as earlier biochemical recurrence, shorter disease-free survival and decreased time to initiation of hormone therapy.
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Some studies have evaluated the effect of age on biopsy accuracy. Richstone and colleagues conducted the first major study on this subject. They found that the frequency of upgrading was higher in older patients (≥70 years), but this was not significant on multivariate analysis. Their study found that patients aged ≥70 years are more likely to be upstaged after RP. 23 In another study, Bright and colleagues found no association between age and GS upgrading. 24 In contrast, in a study of 1836 patients, Gershman and colleagues found an association between older age and GS upgrading. 25 Our study shows that age was not a predicting factor of GS upgrading.
Our study has its limitations. Firstly, this study introduces inherent bias due to its retrospective design. Secondly, although it includes pathological data from 2 centres for 6 years, all biopsy and prostatectomy specimens were evaluated with the same Gleason grading criteria by experienced genitourinary pathologists. Thirdly, because previous studies show a high correlation between TRUS volume and pathological prostate weight, we used pathological weight as a surrogate of TRUS volume. Also, our subjects were Turkish natives, so our results may be different with other nationalities. Finally, we evaluated patients with biopsy GS ≤6 who underwent RP; therefore we did not risk attaining an upgrading due to higher grade disease on biopsy. Notwithstanding these limitations, our study is important because it is the first of its kind coming from Turkey.
Conclusion
When obtaining an extended-core biopsy scheme, we found that patients with small prostates (≤40 cc), with >1 positive core for cancer and with an increased burden of cancer in prostate biopsy have a higher risk of GS upgrading. Also, patients with GS upgrading at prostatectomy tend to have poorer outcomes. Therefore, our results have clinical implications for risk-stratification and treatment choice, especially in choosing of non-surgical treatment options, such as active surveillance and watchful waiting, for patients with GS ≤6 on biopsy. This paper has been peer-reviewed.
